New Research on Hybrid Software Group (HYSG-Euronext Brussels)

Posted by Karen Goldfarb

May 11, 2023 at 11:54 AM

An Executive Informational Overview (EIO) is now available on Hybrid Software Group PLC, a developer of software and hardware enterprise solutions for industrial inkjet printing. The 80-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Download Hybrid Software Group Report

Read More

Topics: hybrid software group, hysg, inkjet printing, enterprise software, hardware, global graphics, color logic, ic3d, original equipment manufacturers, hybrid software

May 2023 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

May 9, 2023 at 4:48 PM

Crystal Research Associates has issued an 18-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox

March 2023 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 28, 2023 at 4:41 PM

Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox

New Research Released on CEL-SCI Corporation (CVM-NYSE)

Posted by Karen Goldfarb

March 20, 2023 at 7:13 PM

An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download CEL-SCI Corporation Report

 

Read More

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

New Research on Emmaus Life Sciences, Inc. (EMMA-OTCQX)

Posted by Karen Goldfarb

January 24, 2023 at 3:17 PM

An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Download Emmaus Life Sciences, Inc. Initiation Report

Read More

Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, emmaus life sciences, sickle cell disease, L-glutamine, endari, diverticulosis

December 2022 Update on Bioxytran, Inc. (BIXT-OTCBB)

Posted by Karen Goldfarb

December 21, 2022 at 2:30 PM

A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. 

 

Read More

Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin

November 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 11, 2022 at 4:11 PM

Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox

New Research on SG Blocks, Inc. (SGBX-NASDAQ)

Posted by Karen Goldfarb

September 14, 2022 at 8:29 PM

An Executive Informational Overview (EIO) is now available on SG Blocks, Inc., a leading developer, designer, and fabricator of modular structures, meeting the growing demand for safe and green construction. The 64-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Download SG Blocks, Inc. Initiation Report

Read More

Topics: SG Blocks, modular construction, green building, COVID-19 testing, Starbucks, Taco Bell, Sanitec, green construction, shipping containers, GreenSteel, cargo modified modules, Verizon, Puma, Lacoste, NBA, Equinox, Clarity Lab Solutions, SGBX

New Research on Bioxytran, Inc. (BIXT-OTCBB)

Posted by Karen Goldfarb

August 25, 2022 at 8:46 PM

An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Download Bioxytran, Inc. Initiation Report

Read More

Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin

August 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

August 5, 2022 at 4:02 PM

Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox

New Research on Genprex, Inc. (GNPX-NASDAQ)

Posted by Karen Goldfarb

June 23, 2022 at 7:58 PM

An Executive Informational Overview (EIO) is now available on Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The 62-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Genprex, Inc. Initiation Report

Read More

Topics: cancer,  REQORSA, genprex, diabetes, gene therapy, non-small cell lung cancer, small-cell lung cancer

New Research on ImmunoPrecise Antibodies Ltd (IPA-NASDAQ/IPA-TSX)

Posted by Karen Goldfarb

May 18, 2022 at 11:06 AM

An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download ImmunoPrecise Antibodies Ltd Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)

April 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

April 29, 2022 at 1:23 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19

March 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 14, 2022 at 6:22 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19

New Research Released on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE)

Posted by Karen Goldfarb

March 10, 2022 at 12:14 PM

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download FSD Pharma Inc.  Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, multiple sclerosis, inflammatory, MS, major depressive disorder (MDD), myelin degradation, bipilar disorder

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic